Clinical Trials Browser

Completed × Stomach Neoplasms × Octreotide × Clear all

Esophageal Neoplasms, Stomach Neoplasms, Weight Loss

NCT02381249 2023-11-27

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery

Phase NA Completed

40 enrolled

Gastrointestinal

Duodenal Neoplasms, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition

NCT02385617 2023-11-27

Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer

Phase NA Completed

20 enrolled

Gastrointestinal

Endocrine System Diseases, Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition

NCT00004895 2012-06-06

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Phase 2 Completed

GastrointestinalGynecologicOtherSarcoma

Carcinoma, Ovarian Epithelial, Bile Duct Neoplasms, Colonic Neoplasms, Constipation, Intestinal Obstruction, Nausea, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Clinical Trials

OTIS

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery

Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery